

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit – Unknown

In re

Patent Application of

David Edwin Thurston, et al.

Serial No. Unknown

Filed: December 12, 2001

Examiner: Unknown

“COMPOUNDS”

CERTIFICATION UNDER 37 CFR 1.10

I, Leslie Rector, hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope as “Express Mail Post Office to Addressee,” mailing Label Number EL832142024US, addressed to Assistant Commissioner for Patents, BOX PATENT APPLICATION, Washington, D.C. 20231

Leslie Rector
Signature

December 12, 2001
Date

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, D.C. 20231

Sir:

This application is a continuation of U.S. Patent Application Serial No. 09/763,767, filed under 37 CFR 1.53(b). Prior to examination on the merits, please amend the subject application as follows:

In the Specification:

Please amend the specification as follows:

On page 1, please delete the title “COMPOUNDS”, and replace it with the following:

PYRROLBENZODIAZEPINES

On page 1, immediately before “Background to the invention”, please add the following new paragraph and heading:

CROSS REFERENCE TO RELATED APPLICATIONS

This patent application is a continuation of prior U.S. Patent Application Serial No. 09/763,767, filed on February 26, 2001 which is a filing under 35 U.S.C. 371 based upon International Application No. PCT/GB99/02838, filed on August 27, 1999, which claims priority to Great Britain Application No. 9818733.9, filed on August 27, 1998 and Great Britain Application No. 9901929.1, filed on January 28, 1999.

Replace the third full paragraph on page 205 with the following:

Results for the human ovarian tumour OVCAR-5 were less clear cut; approximately 50% tumour size reduction was observed and some growth delay was observed but activity appeared to be higher at lower concentrations. However, again, no mice died as a result of exposure to UP2001 (80).


Remarks:

Consideration of the foregoing amendments and following remarks is respectfully requested.

The amendment to the specification amends the application to change the title, include the chain of priority, and amend page 205 to correct a typographical error.

For reasons provided above, Applicants respectfully submit that the amendments to the specification introduced herein adds no new matter to the application, as filed.

Respectfully submitted,


Grady J. Frenchick
Reg. No. 29,018

File No. 065435-9010
Michael Best & Friedrich LLP
One South Pinckney Street
P. O. Box 1806
Madison, WI 53701-1806
(608) 257-3501
Q:\CLIENT\065435\9000\B0111605.DOC

“Version with markings to show changes made”

The changes made to the specification are shown by [brackets] for deleted matter, and double underlining for added matter.

In the title.

[COMPOUNDS] PYRROLBENZODIAZEPINES

The third full paragraph on page 205.

Results for the human ovarian tumour OVCAR-5 were less clear cut; approximately 50% tumour size reduction was observed and some growth delay was observed but activity appeared to be higher at lower concentrations. However, again, no mice died as a result of exposure to UP2001 (**80**).